Bioxyne Limited · ASX:BXN
Bioxyne — Q1 FY26 Earnings Presentation
11 slides from Bioxyne's earnings presentation, Oct 30, 2025
Slide 1: Presentation on FY25 Q1 Results
ASX:BXN 30 October 2025 Presentation on FY25 Q1 Results Bioxyne Limited (ASX: BXN) (Bioxyne or Company) is pleased to attach a presentation on the first quarter results for FY2025. For video transcript please see: https://youtu.be/s8gNrn3E7as This presentation approved for release to the ASX by The
Slide 2: About Bioxyne
About Bioxyne Bioxyne Limited (ASX:BXN) is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines. About Breathe Life Sciences (BLS) Brea
Slide 3: Corporate and international websites
f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets. Corporate: bioxyne.com Australia: bls.com.au International: breathelifesciences.com 3
Slide 4: Q1 FY26
CAMBS, = Ps MOMA —_ \ 4 } t ie . 4 : “<, j — ie ae fy rine? 3 (PHARMACEUTICAL GRADE )
Slide 5: Disclaimer
DISCLAIMER This presentation (Presentation) has been prepared by Bioxyne Limited ABN 97 084 464 193 (Bioxyne or the Company). The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this presentation is subjec
Slide 6: Q1 FY26 Overview
Q1 FY26 OVERVIEW 3
Slide 7: Q1 FY26 Overview
Q1 FY26 OVERVIEW The Board reconfirms its guidance of $65m to $75m Revenue for FY26 and $11.5m to $13.5m Underlying EBITDA, underpinned by strong Q1 results Q1 OVERVIEW FINANCIALS OUTLOOK Record quarterly revenue of Substantial investment in Purchase orders from Germany Completed dual listing on $14
Slide 8: Revenue Growth
REVENUE GROWTH Record quarterly revenue of $14 million, representing a 210% increase on Q1 FY25 and a 47% increase on Q4 FY25 Q1 OVERVIEW FINANCIALS OUTLOOK $14.1 million revenue attributable to significant BXN REVENUE BY QUARTER performance by BLS Australia with key growth areas being white label
Slide 9: Cash Flow
CASH FLOW The Company invested an additional $2.5m in inventory and $1.5m in net working capital to meet growing demand Q1 OVERVIEW FINANCIALS OUTLOOK The Company generated cash receipts figure of CASH RECEIPTS & NET CASH USED IN OPERATING ACTIVITIES $12.95m during the quarter, representing a mate
Slide 10: Outlook
OUTLOOK Substantial growth anticipated in FY26 with multiple growth drivers underpinning revenue & margin expansion Q1 OVERVIEW FINANCIALS OUTLOOK EUROPE UK AUS Continue to accelerate Continue to progress controlled Invest in inventory to meet controlled drugs and GMP drugs and GMP manufacturing sig
Slide 11: Contact
CONTACT JAMES EMONSON ALPINE CAPITAL Corporate Advisor jemonson@alpinecapital.au